-
1
-
-
0034266349
-
HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles
-
Beaird SL (2000) HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 40:637-644.
-
(2000)
J Am Pharm Assoc (Wash)
, vol.40
, pp. 637-644
-
-
Beaird, S.L.1
-
2
-
-
25844530136
-
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
-
Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, and Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78: 342-350.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 342-350
-
-
Chung, J.Y.1
Cho, J.Y.2
Yu, K.S.3
Kim, J.R.4
Oh, D.S.5
Jung, H.R.6
Lim, K.S.7
Moon, K.H.8
Shin, S.G.9
Jang, I.J.10
-
3
-
-
0027275566
-
Physiological parameters in laboratory animals and humans
-
Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
-
(1993)
Pharm Res
, vol.10
, pp. 1093-1095
-
-
Davies, B.1
Morris, T.2
-
4
-
-
0034235341
-
Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2
-
Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
-
(2000)
Hepatology
, vol.32
, pp. 82-86
-
-
Fattinger, K.1
Cattori, V.2
Hagenbuch, B.3
Meier, P.J.4
Stieger, B.5
-
5
-
-
77649216536
-
Membrane transporters in drug development
-
International Transporter Consortium
-
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 215-236
-
-
Giacomini, K.M.1
Huang, S.M.2
Tweedie, D.J.3
Benet, L.Z.4
Brouwer, K.L.5
Chu, X.6
Dahlin, A.7
Evers, R.8
Fischer, V.9
Hillgren, K.M.10
-
6
-
-
0036081327
-
Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats
-
Gotoh Y, Kato Y, Stieger B, Meier PJ, and Sugiyama Y (2002) Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. Am J Physiol Endocrinol Metab 282:E1245-E1254.
-
(2002)
Am J Physiol Endocrinol Metab
, vol.282
-
-
Gotoh, Y.1
Kato, Y.2
Stieger, B.3
Meier, P.J.4
Sugiyama, Y.5
-
7
-
-
22944458539
-
Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin
-
Hirano M, Maeda K, Hayashi H, Kusuhara H, and Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876-882.
-
(2005)
J Pharmacol Exp Ther
, vol.314
, pp. 876-882
-
-
Hirano, M.1
Maeda, K.2
Hayashi, H.3
Kusuhara, H.4
Sugiyama, Y.5
-
8
-
-
0037613131
-
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: Probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites
-
Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2002) The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17:23-33.
-
(2002)
Drug Metab Pharmacokinet
, vol.17
, pp. 23-33
-
-
Horikawa, M.1
Kato, Y.2
Tyson, C.A.3
Sugiyama, Y.4
-
9
-
-
84861575094
-
11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver
-
11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. Bioorg Med Chem 20:3703-3709.
-
(2012)
Bioorg Med Chem
, vol.20
, pp. 3703-3709
-
-
Ijuin, R.1
Takashima, T.2
Watanabe, Y.3
Sugiyama, Y.4
Suzuki, M.5
-
10
-
-
0032455502
-
Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide
-
Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, and Sugiyama Y (1998) Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37-42.
-
(1998)
J Pharmacol Exp Ther
, vol.287
, pp. 37-42
-
-
Ishizuka, H.1
Konno, K.2
Naganuma, H.3
Nishimura, K.4
Kouzuki, H.5
Suzuki, H.6
Stieger, B.7
Meier, P.J.8
Sugiyama, Y.9
-
11
-
-
0031916830
-
Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver
-
Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, and Sugiyama Y (1998) Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J Biol Chem 273:1684-1688.
-
(1998)
J Biol Chem
, vol.273
, pp. 1684-1688
-
-
Ito, K.1
Suzuki, H.2
Hirohashi, T.3
Kume, K.4
Shimizu, T.5
Sugiyama, Y.6
-
12
-
-
84865979524
-
Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice
-
Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 9: 2497-2504.
-
(2012)
Mol Pharm
, vol.9
, pp. 2497-2504
-
-
Iusuf, D.1
Sparidans, R.W.2
Van Esch, A.3
Hobbs, M.4
Kenworthy, K.E.5
Van De-Steeg, E.6
Wagenaar, E.7
Beijnen, J.H.8
Schinkel, A.H.9
-
13
-
-
84859908658
-
Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals
-
Kato K, Kusuhara H, Kumagai Y, Ieiri I, Mori H, Ito S, Nakai Y, Maeda K, and Sugiyama Y (2012) Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. Pharmacogenet Genomics 22:344-354.
-
(2012)
Pharmacogenet Genomics
, vol.22
, pp. 344-354
-
-
Kato, K.1
Kusuhara, H.2
Kumagai, Y.3
Ieiri, I.4
Mori, H.5
Ito, S.6
Nakai, Y.7
Maeda, K.8
Sugiyama, Y.9
-
14
-
-
0023707091
-
Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues
-
Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, and Hanano M (1988) Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 77:200-207.
-
(1988)
J Pharm Sci
, vol.77
, pp. 200-207
-
-
Kim, D.C.1
Sugiyama, Y.2
Satoh, H.3
Fuwa, T.4
Iga, T.5
Hanano, M.6
-
15
-
-
85027944328
-
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy
-
Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, Kim SW, Kim MK, Kim KH, and In Lee B, et al. (2010) A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 20:249-256.
-
(2010)
Pharmacogenet Genomics
, vol.20
, pp. 249-256
-
-
Kim, W.J.1
Lee, J.H.2
Yi, J.3
Cho, Y.J.4
Heo, K.5
Lee, S.H.6
Kim, S.W.7
Kim, M.K.8
Kim, K.H.9
In Lee, B.10
-
16
-
-
84879416468
-
Imaging in the study of membrane transporters
-
Kusuhara H (2013) Imaging in the study of membrane transporters. Clin Pharmacol Ther 94:33-36.
-
(2013)
Clin Pharmacol Ther
, vol.94
, pp. 33-36
-
-
Kusuhara, H.1
-
18
-
-
31144438802
-
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems
-
Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
-
(2006)
J Pharmacol Exp Ther
, vol.316
, pp. 762-771
-
-
Lau, Y.Y.1
Okochi, H.2
Huang, Y.3
Benet, L.Z.4
-
19
-
-
25844458977
-
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
-
Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, and Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330-341.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 330-341
-
-
Lee, E.1
Ryan, S.2
Birmingham, B.3
Zalikowski, J.4
March, R.5
Ambrose, H.6
Moore, R.7
Lee, C.8
Chen, Y.9
Schneck, D.10
-
20
-
-
68249101487
-
Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes
-
Li N, Bi YA, Duignan DB, and Lai Y (2009) Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm 6:1180-1189.
-
(2009)
Mol Pharm
, vol.6
, pp. 1180-1189
-
-
Li, N.1
Bi, Y.A.2
Duignan, D.B.3
Lai, Y.4
-
21
-
-
22944446686
-
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein
-
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, and Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059-1067.
-
(2005)
J Pharmacol Exp Ther
, vol.314
, pp. 1059-1067
-
-
Matsushima, S.1
Maeda, K.2
Kondo, C.3
Hirano, M.4
Sasaki, M.5
Suzuki, H.6
Sugiyama, Y.7
-
22
-
-
0033623722
-
Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2
-
Morikawa A, Goto Y, Suzuki H, Hirohashi T, and Sugiyama Y (2000) Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm Res 17:546-552.
-
(2000)
Pharm Res
, vol.17
, pp. 546-552
-
-
Morikawa, A.1
Goto, Y.2
Suzuki, H.3
Hirohashi, T.4
Sugiyama, Y.5
-
23
-
-
45949102855
-
Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs
-
Nies AT, Schwab M, and Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568.
-
(2008)
Expert Opin Drug Metab Toxicol
, vol.4
, pp. 545-568
-
-
Nies, A.T.1
Schwab, M.2
Keppler, D.3
-
24
-
-
0038209381
-
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics
-
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, and Urasaki Y, et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 554-565
-
-
Nishizato, Y.1
Ieiri, I.2
Suzuki, H.3
Kimura, M.4
Kawabata, K.5
Hirota, T.6
Takane, H.7
Irie, S.8
Kusuhara, H.9
Urasaki, Y.10
-
25
-
-
33751096467
-
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
-
Pasanen MK, Neuvonen M, Neuvonen PJ, and Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 873-879
-
-
Pasanen, M.K.1
Neuvonen, M.2
Neuvonen, P.J.3
Niemi, M.4
-
26
-
-
36148953896
-
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
-
Pasanen MK, Fredrikson H, Neuvonen PJ, and Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 726-733
-
-
Pasanen, M.K.1
Fredrikson, H.2
Neuvonen, P.J.3
Niemi, M.4
-
27
-
-
0036175452
-
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport
-
Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res 19:147-153.
-
(2002)
Pharm Res
, vol.19
, pp. 147-153
-
-
Shitara, Y.1
Sugiyama, D.2
Kusuhara, H.3
Kato, Y.4
Abe, T.5
Meier, P.J.6
Itoh, T.7
Sugiyama, Y.8
-
28
-
-
0025355830
-
Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
-
Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29:239-243.
-
(1990)
Br J Clin Pharmacol
, vol.29
, pp. 239-243
-
-
Singhvi, S.M.1
Pan, H.Y.2
Morrison, R.A.3
Willard, D.A.4
-
29
-
-
78149251941
-
Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18, 19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport
-
Takashima T, Nagata H, Nakae T, Cui Y, Wada Y, Kitamura S, Doi H, Suzuki M, Maeda K, and Kusuhara H, et al. (2010) Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J Pharmacol Exp Ther 335:314-323.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 314-323
-
-
Takashima, T.1
Nagata, H.2
Nakae, T.3
Cui, Y.4
Wada, Y.5
Kitamura, S.6
Doi, H.7
Suzuki, M.8
Maeda, K.9
Kusuhara, H.10
-
30
-
-
80053490330
-
11C]telmisartan
-
11C]telmisartan. Mol Pharm 8:1789-1798.
-
(2011)
Mol Pharm
, vol.8
, pp. 1789-1798
-
-
Takashima, T.1
Hashizume, Y.2
Katayama, Y.3
Murai, M.4
Wada, Y.5
Maeda, K.6
Sugiyama, Y.7
Watanabe, Y.8
-
31
-
-
79958109274
-
11C-oseltamivir
-
11C-oseltamivir. J Nucl Med 52:950-957.
-
(2011)
J Nucl Med
, vol.52
, pp. 950-957
-
-
Takashima, T.1
Yokoyama, C.2
Mizuma, H.3
Yamanaka, H.4
Wada, Y.5
Onoe, K.6
Nagata, H.7
Tazawa, S.8
Doi, H.9
Takahashi, K.10
-
32
-
-
84860781184
-
11C-TIC-Me
-
11C-TIC-Me. J Nucl Med 53: 741-748.
-
(2012)
J Nucl Med
, vol.53
, pp. 741-748
-
-
Takashima, T.1
Kitamura, S.2
Wada, Y.3
Tanaka, M.4
Shigihara, Y.5
Ishii, H.6
Ijuin, R.7
Shiomi, S.8
Nakae, T.9
Watanabe, Y.10
-
33
-
-
59649130318
-
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans
-
Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
-
(2009)
J Pharmacol Exp Ther
, vol.328
, pp. 652-662
-
-
Watanabe, T.1
Kusuhara, H.2
Maeda, K.3
Shitara, Y.4
Sugiyama, Y.5
-
35
-
-
0027392882
-
Na(1)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
-
Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, and Sugiyama Y (1993) Na(1)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
-
(1993)
Am J Physiol
, vol.264
-
-
Yamazaki, M.1
Suzuki, H.2
Hanano, M.3
Tokui, T.4
Komai, T.5
Sugiyama, Y.6
-
36
-
-
0029859136
-
Uptake is the ratelimiting step in the overall hepatic elimination of pravastatin at steady-state in rats
-
Yamazaki M, Akiyama S, Nishigaki R, and Sugiyama Y (1996) Uptake is the ratelimiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 13:1559-1564.
-
(1996)
Pharm Res
, vol.13
, pp. 1559-1564
-
-
Yamazaki, M.1
Akiyama, S.2
Nishigaki, R.3
Sugiyama, Y.4
-
37
-
-
0030862073
-
Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter
-
Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, and Sugiyama Y (1997) Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25: 1123-1129.
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 1123-1129
-
-
Yamazaki, M.1
Akiyama, S.2
Ni'inuma, K.3
Nishigaki, R.4
Sugiyama, Y.5
-
38
-
-
84872234822
-
Hepatic and intestinal drug transporters: Prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms
-
Yoshida K, Maeda K, and Sugiyama Y (2013) Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol 53:581-612.
-
(2013)
Annu Rev Pharmacol Toxicol
, vol.53
, pp. 581-612
-
-
Yoshida, K.1
Maeda, K.2
Sugiyama, Y.3
-
39
-
-
47949104688
-
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin
-
Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, and Ware JA (2008) Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74:320-329.
-
(2008)
Mol Pharmacol
, vol.74
, pp. 320-329
-
-
Zaher, H.1
Meyer Zu-Schwabedissen, H.E.2
Tirona, R.G.3
Cox, M.L.4
Obert, L.A.5
Agrawal, N.6
Palandra, J.7
Stock, J.L.8
Kim, R.B.9
Ware, J.A.10
|